(anecdotal from my side, more around 50%). So to find such a high rate of features annotated to the E. pela proteins is surprising. It might be that E. pela is lucky and does indeed find most of its proteins to have a documented ortholog, but also considering the previous point on gene prediction, I think the authors are currently dealing with a smaller, more conserved part of the E. pela proteome. As a check, I did a quick GeneMark-ET (self-trained) on the genome file. It gave 47,125 potential genes. This is likely a gross overestimation, but inputting these into an Augustus hints file followed by Augustus gene prediction will likely filter out most false positives and give you a much more realistic number of genes. I would like the authors to redo their gene prediction using non-homology methods, e.g. using GeneMark ET self-training, and by using their BLASTN and RNA-Seq results as a hints file input to Augustus. The GeneMark ET self-training results might also serve as hints input to Augustus. If the gene predictions do not significantly differ with their current gene predictions, the authors are indeed dealing with a more-or-less correct gene-set / proteome of E. pela. However, if it differs significantly, they will have to take an in-depth look at using the new genes, or merging them with the previous genes. This would also require the authors to redo their whole downstream analysis, as this is all based on the assumption that the gene set they have is accurate. I do not believe redoing this analysis, including the gene prediction, is extremely time consuming and think the authors should be able to do this in a reasonable time frame. * Table 3 shows the authors also predicted genes with MAKER, but no mention has been made of this in the main text. The authors should clarify why they used MAKER, and if they used the MAKER output in their final results. ** Table 4 shows the functional annotation of E. pela. However, I think the authors miss-use the definition of 'functional annotation' here. All categories except for 'GO-Annotated' don't necessarily provide a functional annotation, as functional annotations are usually GO terms. The authors state that 87.99% of the proteins have a functional annotation, but they do this by counting every protein that falls under one of the categories in table 4. The category of GO-annotated proteins is only 32.23%. Page 10 line 45-46 The authors state they used BUSCO to asses coding gene completeness but they don't mention a number or any other details. The BUSCO summary file is available but should be mentioned in the text. Additionally the authors state they assessed coding gene completeness, but the command line in '9_BUSCO_output_full_table_arthropoda" has '-m genome' as an option, which means they assessed genome completeness not gene completeness. Finally, the authors BUSCO Augustus gene prediction uses fly (drosophila) instead of the aphid they used in their own Augustus gene prediction. If they want to do a genome completeness assessment with Busco the authors should change it to the aphid. Minor points Page 13 Line 17 to 20 Did the authors trim poorly aligned sequence regions in the after multiple-sequence alignment and before the creation of 'super genes'? If not, it is likely that these poorly aligned regions influence the phylogenetic tree in a negative way. Figure 4 Cafe gives a p-value to see if there is a significant change in expansion or contraction. The authors should provide these. GO Terms and other annotations to the genes/proteins I can't find them. Where are they?
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